Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Novo Nordisk's oral Wegovy boosts obesity market, driving strong sales and raised 2026 guidance with $75 target.
NVO
$50.43
+$1.66 +3.40%

Novo Nordisk's oral Wegovy boosts obesity market, driving strong sales and raised 2026 guidance with $75 target.

Analyst Insights
04 Jul 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Novo Nordisk is rated a BUY as its oral Wegovy drug rapidly expands the obesity treatment market in the U.S., with over 3 million prescriptions in five months, mostly from patients new to GLP-1 treatments. This strong demand has led management to raise its 2026 sales guidance, supported by broader Medicare access and international launches. The company's fundamentals are improving faster than its stock price, suggesting potential upside toward a $75 target. Continued growth in GLP-1 sales and global market expansion are key drivers for the positive outlook.

More News (NVO)

FGF21 emerges as key next step beyond GLP-1 in obesity and cardiometabolic treatment, with $10.7B in pharma deals.

FGF21 emerges as key next step beyond GLP-1 in obesity and cardiometabolic treatment, with $10.7B in pharma deals.

PatentVest released a report highlighting FGF21 as the next major therapeutic focus beyond GLP-1 for obesity and cardiometabolic diseases. The report analyzes over $10.7 billion in recent acquisitions and licensing by pharma giants like Novo Nordisk,...

Market News
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App